+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast 2025-2030- Product Image
Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast 2025-2030- Product Image
Sale

Cancer Monoclonal Antibodies Market by Mechanism Of Action, Target Antigen, Antibody Type, Therapeutic Indication, Route Of Administration, End User, Formulation - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010626
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer monoclonal antibodies market is evolving rapidly, propelled by ongoing advancements in antibody engineering, targeted cancer therapies, and a global shift towards precision oncology. Senior decision-makers require a concise overview of the market's changing landscape, emerging technologies, and strategic imperatives to navigate the opportunities and challenges ahead.

Market Snapshot: Cancer Monoclonal Antibodies Market Overview

The Cancer Monoclonal Antibodies Market grew from USD 78.60 billion in 2024 to USD 88.89 billion in 2025. It is expected to continue growing at a CAGR of 12.98%, reaching USD 163.49 billion by 2030. This sector is experiencing robust momentum as next-generation antibodies, improved clinical outcomes, and personalized oncology approaches fuel adoption across global healthcare systems.

Scope & Segmentation

This report delivers comprehensive coverage of market segmentation and regional trends shaping cancer monoclonal antibody development:

  • Mechanisms of Action: Antibody drug conjugates, bispecific antibodies, checkpoint inhibitors, radioimmunotherapy
  • Target Antigens: CD20, HER2, PD-1/PD-L1, VEGF
  • Antibody Types: Chimeric, fully human, humanized, murine
  • Therapeutic Indications: Breast cancer, colorectal cancer, lung cancer, lymphoma
  • Route of Administration: Intravenous, subcutaneous
  • End Users: Cancer research centers, contract research organizations, hospitals, specialty clinics
  • Formulations: Liquid, lyophilized powder
  • Regions: Americas (with detailed sub-region breakdown), Europe/Middle East/Africa, and Asia-Pacific, including key national and subnational markets
  • Leading Companies: Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Novartis AG, Eli Lilly and Company, Sanofi S.A., Daiichi Sankyo Company, Limited

Key Takeaways for Strategic Decision-Makers

  • Monoclonal antibodies continue to advance cancer treatment by supporting targeted, personalized approaches and reducing toxicity compared to traditional therapies.
  • Integration of antibody drug conjugates, bispecific platforms, and checkpoint inhibitors is shifting clinical paradigms, enabling combination regimens that address complex tumor biology and resistance mechanisms.
  • Pharmaceutical collaboration with academic institutions and regulatory bodies is streamlining pipeline progression, converting promising innovations into approved therapies faster.
  • Expansion into new indications, alongside established use in breast cancer and hematological malignancies, reflects growing focus on addressing high unmet medical needs in solid tumors.
  • Stakeholders are building supply chain resilience and manufacturing scalability to ensure reliable drug access and cost efficiency amid intensifying global demand.
  • Enhanced real-world evidence and digital integration are increasingly essential to validate value, inform reimbursement, and support patient stratification strategies.

Cancer Monoclonal Antibodies Market: Tariff Impact and Innovation

Recent United States tariffs on biopharmaceutical imports are increasing cost pressures on raw materials, manufacturing, and specialized reagents crucial for monoclonal antibody production. Organizations are reassessing supply chain footprints, exploring domestic sourcing alternatives, and investing in localized manufacturing capacities. This challenging landscape accelerates the adoption of digital supply chain tools, encourages long-term vendor agreements, and prompts cross-industry collaborations to share best practices and mitigate risk. Regulatory engagement and public-private initiatives are also emerging to address the impact of tariffs on critical oncology assets.

Methodology & Data Sources

This report employs a rigorous mix of primary and secondary research. Primary interviews with scientific, clinical, and supply chain experts validate key trends. Secondary analysis includes peer-reviewed publications, clinical trial data, regulatory filings, and company disclosures. Cross-referencing of qualitative and quantitative findings ensures data reliability and factual accuracy.

Why This Report Matters

  • Equips senior leaders with actionable insights into segmentation, regional trends, and innovation strategies to inform investment and portfolio moves.
  • Enables agile supply network and market entry planning by highlighting cost, regulatory, and operational dynamics across global regions.
  • Facilitates strategic partnerships and early engagement with regulators and payers by providing clarity on technology adoption, reimbursement frameworks, and value-based care.

Conclusion

Cancer monoclonal antibodies remain central to oncology innovation. By leveraging the insights in this report, industry leaders can optimize strategy, bolster resilience, and lead in the evolving landscape of targeted cancer therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid expansion of bispecific monoclonal antibodies targeting dual tumor antigens in solid tumors
5.2. Increasing adoption of antibody-drug conjugates with novel cytotoxic payloads for resistant cancers
5.3. Integration of immune checkpoint monoclonal antibodies with personalized CAR-T therapies in clinical trials
5.4. Development of Fc-engineered monoclonal antibodies to enhance effector functions in hematologic malignancies
5.5. Emergence of biosimilar monoclonal antibody competition driving price reductions in prostate cancer treatments
5.6. Growing investment in multispecific antibody platforms combining checkpoint inhibition and cytokine delivery
5.7. Implementation of real-world evidence to optimize monoclonal antibody dosing and treatment sequencing
5.8. Application of AI-driven epitope mapping to accelerate discovery of next-generation cancer monoclonal antibodies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Monoclonal Antibodies Market, by Mechanism Of Action
8.1. Introduction
8.2. Antibody Drug Conjugates
8.2.1. DNA Alkylating Agents
8.2.2. Microtubule Inhibitors
8.3. Bispecific Antibodies
8.3.1. Dual Checkpoint Modulators
8.3.2. T Cell Engagers
8.4. Checkpoint Inhibitors
8.4.1. CTLA-4
8.4.2. PD-1
8.4.3. PD-L1
8.5. Radioimmunotherapy
8.5.1. Alpha Emitters
8.5.2. Beta Emitters
9. Cancer Monoclonal Antibodies Market, by Target Antigen
9.1. Introduction
9.2. CD20
9.3. HER2
9.4. PD-1/PD-L1
9.5. VEGF
10. Cancer Monoclonal Antibodies Market, by Antibody Type
10.1. Introduction
10.2. Chimeric
10.3. Fully Human
10.4. Humanized
10.5. Murine
11. Cancer Monoclonal Antibodies Market, by Therapeutic Indication
11.1. Introduction
11.2. Breast Cancer
11.3. Colorectal Cancer
11.4. Lung Cancer
11.5. Lymphoma
12. Cancer Monoclonal Antibodies Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Subcutaneous
13. Cancer Monoclonal Antibodies Market, by End User
13.1. Introduction
13.2. Cancer Research Center
13.3. Contract Research Organization
13.4. Hospital
13.5. Specialty Clinic
14. Cancer Monoclonal Antibodies Market, by Formulation
14.1. Introduction
14.2. Liquid
14.3. Lyophilized Powder
15. Americas Cancer Monoclonal Antibodies Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Cancer Monoclonal Antibodies Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Cancer Monoclonal Antibodies Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Roche Holding AG
18.3.2. Merck & Co., Inc.
18.3.3. Bristol-Myers Squibb Company
18.3.4. AstraZeneca PLC
18.3.5. Johnson & Johnson
18.3.6. Takeda Pharmaceutical Company Limited
18.3.7. Novartis AG
18.3.8. Eli Lilly and Company
18.3.9. Sanofi S.A.
18.3.10. Daiichi Sankyo Company, Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. CANCER MONOCLONAL ANTIBODIES MARKET: RESEARCHAI
FIGURE 30. CANCER MONOCLONAL ANTIBODIES MARKET: RESEARCHSTATISTICS
FIGURE 31. CANCER MONOCLONAL ANTIBODIES MARKET: RESEARCHCONTACTS
FIGURE 32. CANCER MONOCLONAL ANTIBODIES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY DNA ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY DNA ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROTUBULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROTUBULE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY DUAL CHECKPOINT MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY DUAL CHECKPOINT MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY T CELL ENGAGERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY T CELL ENGAGERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CTLA-4, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CTLA-4, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-1, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-1, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-L1, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-L1, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BETA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CD20, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CD20, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HER2, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HER2, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-1/PD-L1, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY PD-1/PD-L1, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY VEGF, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY VEGF, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 145. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 146. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 147. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 148. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 149. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 150. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 151. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 156. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 157. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 158. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 159. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 160. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 161. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 166. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 167. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 168. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 169. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 170. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 171. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 172. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 173. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 176. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 177. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 178. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 179. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 180. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 181. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 182. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 183. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 188. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 279. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 280. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 281. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 282. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 283. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 284. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 285. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 286. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 287. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 288. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 289. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 290. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 291. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2018-2024 (USD MILLION)
TABLE 292. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY TYPE, 2025-2030 (USD MILLION)
TABLE 293. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2024 (USD MILLION)
TABLE 294. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025-2030 (USD MILLION)
TABLE 295. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 201

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer Monoclonal Antibodies market report include:
  • Roche Holding AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Eli Lilly and Company
  • Sanofi S.A.
  • Daiichi Sankyo Company, Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 88.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 163.49 Billion
Compound Annual Growth Rate12.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Humanized Monoclonal Antibody Market by Disease Indication (Autoimmune, Cardiovascular, Infectious Diseases), Target Class (CD Antigens, Checkpoint Inhibitors, Cytokines), Route of Administration, End Use, Distribution Channel - Global Forecast 2025-2030 - Product Image

Humanized Monoclonal Antibody Market by Disease Indication (Autoimmune, Cardiovascular, Infectious Diseases), Target Class (CD Antigens, Checkpoint Inhibitors, Cytokines), Route of Administration, End Use, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Fully Humanized Monoclonal Antibody Market by Manufacturing System (Mammalian Cell Culture, Microbial Expression), Antibody Class (IgG1, IgG2, IgG4), Indication, Distribution Channel, End User, Target - Global Forecast 2025-2030 - Product Image

Fully Humanized Monoclonal Antibody Market by Manufacturing System (Mammalian Cell Culture, Microbial Expression), Antibody Class (IgG1, IgG2, IgG4), Indication, Distribution Channel, End User, Target - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Antibodies Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Antibodies Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2025-2033 - Product Image

Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2025-2033

  • Report
  • 147 Pages
  • Global
From
Cancer Monoclonal Antibodies Market Report 2025 - Product Image

Cancer Monoclonal Antibodies Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.